UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________________________________

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934

For the month of October, 2011

Commission File Number ________________


Novogen Limited
(Translation of registrant’s name into English)

140 Wicks Road, North Ryde, NSW, Australia
(Address of principal executive office)
___________________________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x   Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(l):   o

Note: Regulation S-T Rule 101 (b)( I) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule lO1(b)(7): o

Note: Regulation S-T Rule l01(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule l2g3-2(b) under the Securities Exchange Act of 1934. Yes o   No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Novogen Limited
(Registrant)
/s/  Ron Erratt
Ronald Lea Erratt
Company Secretary
Date 1 November, 2011

 


 
 
 
 
 
 
 
 
NOVOGEN LOGO
 
31 October, 2011

The Manager Companies
Australian Securities Exchange
20 Bridge Street
SYDNEY   NSW   2000

Dear Sir

Novogen Annual General Meeting 2011
1.  
Results of Meeting
In accordance with Listing Rule 3.13.2 and 251 AA of the Corporations Act, details of Annual Meeting resolutions and proxies received in respect of each resolution are set out in the tables below.

Resolution details are as follows:
         
2)
Adopt the Remuneration Report year end 30/06/2011
 
The instructions given to validly appointed proxies in respect of the resolution were as follows:
         
 
For
Against
Abstain
Proxy's discretion
 
32,213,070
1,469,117
33,758
17,000
         
carried
The motion was carried as an ordinary resolution on a show of hands.
         
3)
To Re-elect Mr Josiah T Austin as a Director
 
The instructions given to validly appointed proxies in respect of the resolution were as follows:
         
 
For
Against
Abstain
Proxy's discretion
 
37,532,518
844,263
65,825
150,901
         
carried
The motion was carried as an ordinary resolution on a show of hands.
         
4)
To re-elect Mr Peter DA Scutt as a Director
 
The instructions given to validly appointed proxies in respect of the resolution were as follows:
         
 
For
Against
Abstain
Proxy's discretion
 
37,608,748
768,033
65,825
150,901
         
carried
The motion was carried as an ordinary resolution on a show of hands.

Yours faithfully


/s/ Ron Erratt

Ron Erratt
Company Secretary
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Kazia Therapeutics Charts.
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Kazia Therapeutics Charts.